Change over period: —
NSE · MARKSANS
MARKSANS
-15.3% from the 52-week high · +87.7% above the low
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 1,412 full-time employees. The company went IPO on 2002-04-03. The firm operates through the manufacture of pharmaceutical formulation segment. The firm is primarily engaged in the research, manufacturing and marketing of generic pharmaceutical formulations with three state-of-the-art facilities in India, the United Kingdom and the United States. The company marks its presence across different therapeutic areas in the region, such as pain management, diabetes, cough and cold, neurology, cardiovascular and hormonal treatment. The firm has a manufacturing facility for the manufacture of oral solid tablets, soft gelatin capsules and hard capsules in Goa. The company also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The firm has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
The short version. MARKSANS reported revenue of ₹940 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹141 crore (up 43.9% year on year). Return on equity was 13.8% in Mar 2026. Promoter holding was 43.87% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
MARKSANS trades 15.3% below its 52-week high and 87.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹940 cr.
Sep 2026 net profit of ₹141 cr.
1.4 pts higher than a year earlier.
Revenue compounded at 16.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 940 | 841 | 856 | 754 | 720 | 620 | 71 | 682 |
| Net profit | 141 | 157 | 148 | 113 | 98 | 58 | 9 | 105 |
| Net margin % | 15.0 | 18.7 | 17.3 | 15.0 | 13.6 | 9.4 | 12.8 | 15.3 |
| EPS (₹) | 3.12 | 3.47 | 3.27 | 2.5 | 2.17 | 1.29 | 0.2 | 2.31 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2951 | 262 | 2177 | 1852 | 1491 | 1376 | 1134 | 1000 |
| Net profit | 418 | 38 | 314 | 265 | 187 | 239 | 121 | 76 |
| Net margin % | 14.2 | 14.6 | 14.4 | 14.3 | 12.5 | 17.3 | 10.6 | 7.6 |
| EPS (₹) | 9.22 | 0.84 | 6.93 | 5.85 | 4.56 | 5.83 | 2.95 | 1.86 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 13.8% in Mar 2026; debt to equity is 0.01.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 13.8 | 15.5 | 15.2 | 15.2 |
| Return on capital % | 17.5 | 18.7 | 19.0 | 18.8 |
| EBITDA margin % | 22.5 | 22.2 | 22.9 | 20.9 |
| Net margin % | 13.8 | 14.2 | 14.1 | 13.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 16.6% | 17.0% |
| Profit CAGR | 16.4% | 11.9% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Down 2.9 pts over 8 quarters.
Up 1.24 pts over 8 quarters.
+8 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 43.87 | 43.87 | 43.87 | 43.87 | 43.87 | 43.87 | 43.87 | 43.87 | 0.0 |
| FII | 21.96 | 22.2 | 19.88 | 16.92 | 8.12 | 16.76 | 17.47 | 19.06 | -2.9 |
| DII | 4.3 | 4.56 | 5.5 | 5.28 | 5.91 | 6.57 | 6.19 | 5.54 | +1.24 |
| Public | 29.87 | 29.37 | 30.75 | 33.93 | 42.09 | 32.79 | 32.47 | 31.53 | +1.66 |
Mutual fund holdings · Oct 2026
31 schemes hold this stock
23 the month before.
- Kotak MNC Fund2.91% of NAV
- Kotak Special Opportunities Fund2.6% of NAV
- Kotak Healthcare Fund2.22% of NAV
- UTI - Healthcare Fund2.14% of NAV
- Unifi Flexi Cap Fund2.06% of NAV
- UTI Small Cap Fund1.92% of NAV
- SAMCO ACTIVE MOMENTUM FUND1.75% of NAV
- Old Bridge Flexi Cap Fund1.57% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for MARKSANS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about MARKSANS
What is the MARKSANS share price?
MARKSANS (MARKSANS) last closed at ₹299.05, up 1.54% on the day. Its 52-week range is ₹156.89 to ₹347.60.
What is the market cap of MARKSANS?
MARKSANS has a market capitalisation of about ₹13,384 crore. Its price-to-earnings ratio is 24.0.
How are MARKSANS's latest results?
MARKSANS reported revenue of ₹940 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹141 crore (up 43.9% year on year). Return on equity was 13.8% in Mar 2026. Promoter holding was 43.87% in Sep 2026, up 0.00 points over 8 quarters.
Who owns MARKSANS?
As of Sep 2026, shareholding was: Promoter 43.87%, FII 19.06%, DII 5.54%, Public 31.53%.
How many mutual funds hold MARKSANS?
31 mutual fund schemes held MARKSANS in October 2026. That compares with 23 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 01 Aug 2025 · Final Dividend - Rs. 0.8
- 17 Sep 2024 · Final Dividend - Rs. 0.6
- 07 Jun 2023 · Final Dividend - Rs. 0.5
- 19 Aug 2022 · Final Dividend - Rs. 0.25
- 15 Sep 2021 · Final Dividend - Rs. 0.25
- 22 Sep 2020 · Final Dividend - Rs. 0.1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.